0000000000009331

AUTHOR

Emanuela Marchesi

showing 2 related works from this author

An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).

2018

e23502Background: Trabectedin (T) is approved for patients (pts) with STS after failure of anthracyclines (A) and ifosfamide (I), or pts unsuited to receive AI. ISG performed a retrospective study ...

OncologyCancer Researchmedicine.medical_specialtyIfosfamidebusiness.industrySoft tissue sarcomaRetrospective cohort studymacromolecular substancesmedicine.diseasecarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicineotorhinolaryngologic diseasesbacteriaMedicineObservational studyIn patientSarcomabusinessTrabectedinmedicine.drugJournal of Clinical Oncology
researchProduct

Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group

2021

The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1–40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (p &lt

0301 basic medicineLeiomyosarcomaCancer Researchmedicine.medical_specialtyDacarbazinelcsh:RC254-282GastroenterologyArticlePazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalObservationalTrabectedinSoft tissue sarcomaPerformance statusbusiness.industrySoft tissue sarcomaReal-lifelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisSarcomabusinessmedicine.drugTrabectedin
researchProduct